[HTML] springer.comFull View

[HTML][HTML] Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger, C Laplante… - BMC cancer, 2015 - Springer
Background Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …
被引用次数：86 相关文章
[HTML] nih.gov

[HTML][HTML] Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger, C Laplante… - BMC Cancer, 2015 - ncbi.nlm.nih.gov
Background Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …
[PDF] cyberleninka.org

[PDF][PDF] Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger, C Laplante… - 2015 - cyberleninka.org
Background: Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger, C Laplante… - BMC Cancer, 2015 - go.gale.com
Background Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger, C Laplante… - BMC Cancer, 2015 - infona.pl
Background Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …
[PDF] psu.edu

[PDF][PDF] Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger, C Laplante… - 2015 - Citeseer
Background: Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger… - BMC …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …
[HTML] biomedcentral.com

[HTML][HTML] Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger… - BMC …, 2015 - bmccancer.biomedcentral.com
Platinum-based combination therapy is the standard first-line treatment for women with
advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will not respond …
[PDF] core.ac.uk

[PDF][PDF] Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

D Lane, I Matte, P Garde-Granger, C Laplante… - 2015 - core.ac.uk
Background: Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

D Lane, I Matte, P Garde-Granger, C Laplante… - BMC Cancer, 2015 - europepmc.org
Background Platinum-based combination therapy is the standard first-line treatment for
women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20% will …